scilogo.jpg
SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc.
August 24, 2022 07:30 ET | SciSparc Ltd
Results indicate significant decrease in cocaine craving in a sub-group that received the treatment TEL AVIV, Israel, Aug. 24, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a...
scilogo.jpg
SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction
June 02, 2022 08:30 ET | SciSparc Ltd
No dedicated treatment currently available for cocaine addiction TEL AVIV, Israel, June 02, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical...
Picture1.jpg
Mark Haden, Psychedelic Medicine Expert, Joins Clearmind Medicine’s Advisory Board
August 03, 2021 07:00 ET | Clearmind Medicine
Toronto, Aug. 03, 2021 (GLOBE NEWSWIRE) --  Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of...
Clearmind Issues Shareholder Letter
July 20, 2021 07:00 ET | Clearmind Medicine
Toronto, July 20, 2021 (GLOBE NEWSWIRE) -- via InvestorWire-- Clearmind Medicine Inc. (CSE: CMND) ("Clearmind" or the "Company"), a psychedelic medicine biotech company focused on the discovery and...